Advice
Following a full submission
mitotane (Lysodren) is not recommended for use within NHS Scotland for the symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of mitotane on non-functional adrenal cortical carcinoma is not established.
Mitotane relieves the symptoms of advanced adrenal cortical carcinoma, but there is insufficient evidence to support an increase in survival. The economic case has not been demonstrated.
Mitotane should be used only within the context of clinical trials
Download detailed advice49KB (PDF)
Medicine details
- Medicine name:
- mitotane 500 mg tablets (Lysodren)
- SMC ID:
- 328/06
- Indication:
- Advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma
- Pharmaceutical company
- Laboratoire HRA Pharma
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 11 December 2006